Researching | Synthesis and preliminary biological evaluation of a novel PET tracer for α-synuclein PET imaging

NUCLEAR TECHNIQUES, Volume. 47, Issue 10, 100301(2024)

Synthesis and preliminary biological evaluation of a novel PET tracer for α-synuclein PET imaging

Ce WANG^1,2, Donghui PAN², Siyi TAN², Lizhen WANG², Xinyu WANG², Junjie YAN², Chongyang CHEN², Yuping XU^2、**, and Lianghua ZOU^1、*

Author Affiliations

¹School of Life Science and Health Engineering, Jiangnan University, Wuxi 214122, China

²Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China

show less

Abstract Get PDF(in Chinese)

Figures&Tables (6)

References (34)

Paper Information

References(34)

[1] Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer's disease[J]. Archives of Pharmacal Research, 36, 375-399(2013).

[3] Poewe W, Seppi K, Tanner C M et al. Parkinson disease[J]. Nature Reviews Disease Primers, 3, 17013(2017).

[4] Fayyad M, Salim S, Majbour N et al. Parkinson's disease biomarkers based on α-synuclein[J]. Journal of Neurochemistry, 150, 626-636(2019).

[5] Bloem B R, Okun M S, Klein C. Parkinson's disease[J]. Lancet, 397, 2284-2303(2021).

[6] Pinnell J R, Cui M, Tieu K. Exosomes in Parkinson disease[J]. Journal of Neurochemistry, 157, 413-428(2021).

[7] Recchia A, Debetto P, Negro A et al. Alpha-synuclein and Parkinson's disease[J]. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 18, 617-626(2004).

[8] O'Hara D M, Kalia S K, Kalia L V. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease[J]. Critical Reviews in Clinical Laboratory Sciences, 57, 291-307(2020).

[9] Atik A, Stewart T, Zhang J. Alpha-synuclein as a biomarker for Parkinson's disease[J]. Brain Pathology, 26, 410-418(2016).

[10] Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future[J]. Journal of Internal Medicine, 284, 643-663(2018).

[11] McCluskey S P, Plisson C, Rabiner E A et al. Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development[J]. European Journal of Nuclear Medicine and Molecular Imaging, 47, 451-489(2020).

[12] Uzuegbunam B C, Librizzi D, Hooshyar Yousefi B. PET radiopharmaceuticals for Alzheimer's disease and Parkinson's disease diagnosis, the current and future landscape[J]. Molecules, 25, 977(2020).

[13] Yu L H, Cui J Q, Padakanti P K et al. Synthesis and in vitro evaluation of α-synuclein ligands[J]. Bioorganic & Medicinal Chemistry, 20, 4625-4634(2012).

[14] Verdurand M, Levigoureux E, Lancelot S et al. Amyloid-beta radiotracer[18F]BF-227 does not bind to cytoplasmic glial inclusions of postmortem multiple system atrophy brain tissue[J]. Contrast Media & Molecular Imaging, 2018, 9165458(2018).

[15] Verdurand M, Levigoureux E, Zeinyeh W et al. In silico, in vitro, and in vivo evaluation of new candidates for α-synuclein PET imaging[J]. Molecular Pharmaceutics, 15, 3153-3166(2018).

[16] Ono M, Takahashi M, Shimozawa A et al. In vivo visualization of propagating α-synuclein pathologies in mouse and marmoset models by a bimodal imaging probe, C05-05[J/OL]. bioRxiv(2020).

[17] Xiang J, Tao Y Q, Xia Y Y et al. Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies[J]. Cell, 186, 3350-3367.e19(2023).

[18] Di Nanni A, Saw R S, Battisti U M et al. A fluorescent probe as a lead compound for a selective α-synuclein PET tracer: development of a library of 2-styrylbenzothiazoles and biological evaluation of [18F]PFSB and [18F]MFSB[J]. ACS Omega, 8, 3-31467(2023).

[19] Deeg A A, Reiner A M, Schmidt F et al. Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to α-synuclein aggregates[J]. Biochimica et Biophysica Acta, 1850, 1884-1890(2015).

[20] Orlovskaya V V, Fedorova O S, Viktorov N B et al. One-pot radiosynthesis of [18F]Anle138b—5-(3-bromophenyl)-3-(6-[18F]fluorobenzo[d][1,3]dioxol-5-yl)-1H-pyrazole—a potential PET radiotracer targeting α-synuclein aggregates[J]. Molecules, 28, 2732(2023).

[21] Maurer A, Leonov A, Ryazanov S et al. 11C radiolabeling of anle253b: a putative PET tracer for Parkinson's disease that binds to α-synuclein fibrils in vitro and crosses the blood-brain barrier[J]. ChemMedChem, 15, 411-415(2020).

[22] Kuebler L, Buss S, Leonov A et al. [11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates[J]. European Journal of Nuclear Medicine and Molecular Imaging, 48, 1759-1772(2021).

[23] Raval N R, Madsen C A, Shalgunov V et al. Evaluation of the α-synuclein PET radiotracer (d3)-[11C]MODAG-001 in pigs[J]. Nuclear Medicine and Biology, 114–115, 42-48(2022).

[24] Li B S, Ge P, Murray K A et al. Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel[J]. Nature Communications, 9, 3609(2018).

[25] Tuttle M D, Comellas G, Nieuwkoop A J et al. Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein[J]. Nature Structural & Molecular Biology, 23, 409-415(2016).

[26] Vittorio S, Adornato I, Gitto R et al. Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 35, 1727-1735(2020).

[27] Makaravage K J, Brooks A F, Mossine A V et al. Copper-mediated radiofluorination of arylstannanes with [18F]KF[J]. Organic Letters, 18, 5440-5443(2016).

[28] Xu Y P, Wang L Z, Pan D H et al. Synthesis of a novel 89Zr-labeled HER2 affibody and its application study in tumor PET imaging[J]. EJNMMI Research, 10, 58(2020).

[29] Pan D H, Wang L Z, Wang X Y et al. Optimizing the performance of 68Ga labeled FSHR ligand in prostate cancer model by co-administration of aprotinin[J]. International Journal of Radiation Biology, 98, 1571-1580(2022).

[30] Mason C A, Kossatz S, Carter L M et al. An 89Zr-HDL PET tracer monitors response to a CSF1R inhibitor[J]. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 61, 433-436(2020).

[31] Zeng Q, Cui M C. Current progress in the development of probes for targeting α-synuclein aggregates[J]. ACS Chemical Neuroscience, 13, 552-571(2022).

[32] Gagnon M K J, Hausner S H, Marik J et al. High-throughput in vivo screening of targeted molecular imaging agents[J]. Proceedings of the National Academy of Sciences of the United States of America, 106, 1-17909(2009).

[33] Zhang Y, Wu Q, Ren Y et al. A53T α-synuclein induces neurogenesis impairment and cognitive dysfunction in line M83 transgenic mice and reduces the proliferation of embryonic neural stem cells[J]. Brain Research Bulletin, 182, 118-129(2022).

[34] Kaide S, Watanabe H, Iikuni S et al. Synthesis and evaluation of 18F-labeled chalcone analogue for detection of α-synuclein aggregates in the brain using the mouse model[J]. ACS Chemical Neuroscience, 13, 2982-2990(2022).

[35] Kaide S, Watanabe H, Shimizu Y et al. Identification and evaluation of bisquinoline scaffold as a new candidate for α-synuclein-PET imaging[J]. ACS Chemical Neuroscience, 11, 4254-4261(2020).

Tools

Get Citation

Copy Citation Text

Ce WANG, Donghui PAN, Siyi TAN, Lizhen WANG, Xinyu WANG, Junjie YAN, Chongyang CHEN, Yuping XU, Lianghua ZOU. Synthesis and preliminary biological evaluation of a novel PET tracer for α-synuclein PET imaging[J]. NUCLEAR TECHNIQUES, 2024, 47(10): 100301

Download Citation

EndNote(RIS)BibTex Plain Text

Set citation alerts for article

Save article for my favorites

Paper Information

Category: NUCLEAR CHEMISTRY, RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Received: Feb. 22, 2024

Accepted: --

Published Online: Dec. 13, 2024

The Author Email: XU Yuping (XUYuping), ZOU Lianghua (ZOULianghua)

DOI:10.11889/j.0253-3219.2024.hjs.47.100301

Topics

laser devices and laser physics

Lasers and Laser Optics

laser manufacturing

Instrumentation, Measurement and Metrology